Lactulose solution Rx
Generic Name and Formulations:
Lactulose 10g/15mL; soln; for oral or rectal administration.
Various generic manufacturers
Indications for Lactulose solution:
Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma.
Oral: 30–45mL 3–4 times daily; may adjust dose every day or two to produce 2–3 soft stools daily. Hourly doses of 30–45mL may be used to induce rapid laxation initially; when laxative effect has been achieved, reduce dose to recommended daily dose. Maintenance: continue recommended daily dose. Rectal: may be given as a retention enema via a rectal balloon catheter. Mix 300mL of lactulose solution with 700mL of water or physologic saline, retain for 30–60 minutes. May repeat every 4–6 hours; if evacuated too promptly, may be repeated immediately. Start oral route before stopping enema entirely.
Oral: Individualize dose to produce 2–3 soft stools daily. Infants: initially 2.5–10mL in divided doses. Older children and adolescents: 40–90mL/daily. If initial dose causes diarrhea, reduce dose immediately; discontinue if diarrhea persists.
Patients who require a low galactose diet.
Perform thorough bowel cleansing with non-fermentable solution prior to electrocautery procedures during proctoscopy or colonoscopy. Diabetes. Pregnancy (Cat.B). Nursing mothers.
Avoid concomitant laxatives. Caution with concomitant oral anti-infectives (eg, neomycin); monitor closely. May be antagonized by non-absorbable antacids.
Gas, cramping, diarrhea, nausea, vomiting; infants: also hyponatremia, dehydration.
Formerly known under the brand names Cephulac, Chronulac, Evalose.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage